Gustavo Colombo Dal-Pont

Gustavo Colombo Dal-Pont

Auto-generated profile, based on publicly available information

Gustavo Colombo Dal-Pont

Curso de Medicina, Universidade Alto Vale do Rio do Peixe (UNIARP), Caçador 89500-199, Brazil

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2017 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
SVSamira S. Valvassori
Samira S. Valvassori
WRWilson R. Resende
Wilson R. Resende
GDGustavo Dal‐Pont
Gustavo Dal‐Pont
HSHeron Sangaletti‐Pereira
Heron Sangaletti‐Pereira
FGFernanda F. Gava
Fernanda F. Gava
JQJoão Quevedo
João Quevedo

1 May 2017 in Neuropharmacology
Verified
Journal Article
Closed access
SVSamira S. Valvassori
Samira S. Valvassori
GDGustavo C. Dal-Pont
Gustavo C. Dal-Pont
WRWilson R. Resende
Wilson R. Resende
LJLuciano K. Jornada
Luciano K. Jornada
BPBruna R. Peterle
Bruna R. Peterle
JQJoão Quevedo
João Quevedo

20 July 2018 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
GDGustavo C. Dal-Pont
Gustavo C. Dal-Pont
WRWilson R. Resende
Wilson R. Resende
RVRoger B. Varela
Roger B. Varela
SMSamira Menegas
Samira Menegas
KTKerolen S. Trajano
Kerolen S. Trajano
SVSamira S. Valvassori
Samira S. Valvassori

19 September 2022 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
TPTaise Possamai-Della
Taise Possamai-Della
GDGustavo C. Dal-Pont
Gustavo C. Dal-Pont
WRWilson R. Resende
Wilson R. Resende
JAJorge M. Aguiar-Geraldo
Jorge M. Aguiar-Geraldo
JPJefté Peper-Nascimento
Jefté Peper-Nascimento
SVSamira S. Valvassori
Samira S. Valvassori

7 January 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
CLClaudriana Locatelli
Claudriana Locatelli
KLKarine Luz
Karine Luz
Sergio Fallone AndradeSergio Fallone Andrade
Sergio Fallone Andrade
EBEmyr Hiago Bellaver
Emyr Hiago Bellaver
RORosana Claudio Silva Ogoshi
Rosana Claudio Silva Ogoshi
TCTania Creczynski-Pasa
Tania Creczynski-Pasa
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, is a highly prevalent hepatic condition closely linked to metabolic syndrome (MetS). Epigenetic regulators such as microRNAs (miRNAs) have emerged as critical modulators of the molecular pathways underlying MASLD pathogenesis, offering new perspectives for non-invasive diagnosis and targeted therapy. This study aimed to identify and characterize target genes and pathways regulated by two key hepatic miRNAs, namely miR-122 and miR-29a, through a comprehensive in silico bioinformatics approach, to better understand their functional roles in MASLD and MetS. Methods: Target genes of miR-122 and miR-29a were predicted using three databases (TargetScan, DIANA-microT-CDS, and miRWalk), and those identified by at least two databases were selected for downstream analyses. Functional enrichment was performed using Gene Ontology and KEGG pathway analysis. Gene networks and biological process maps were constructed using Metascape, clusterProfiler and Cytoscape. Results: miR-122 was found to negatively regulate genes involved in lipid metabolism, insulin signaling, and inflammatory pathways, including PPARGC1A, PPARA, LPL, TLR4, and HMGCR, contributing to insulin resistance and liver dysfunction. By contrast, miR-29a demonstrated potential hepatoprotective effects by targeting LEP, INSR, IL13, and IL18, enhancing insulin sensitivity and reducing fibrogenic activity. Enrichment analysis revealed strong associations with biological processes, such as STAT phosphorylation, lipid homeostasis, and inflammatory signaling, as well as associations with cellular components, including lipoproteins and plasma membranes. miR-122 and miR-29a exhibit opposing regulatory functions in MASLD pathogenesis. Whereas miR-122 is associated with disease progression, miR-29a acts protectively. These miRNAs may serve as promising biomarkers and therapeutic targets in MASLD and related metabolic conditions. Further validation through experimental and clinical studies is warranted.

1 January 2024 in Biochemistry Research International
Verified
Journal Article
Open access
EREduardo Bortolon Ribas
Eduardo Bortolon Ribas
GDGustavo Colombo Dal-Pont
Gustavo Colombo Dal-Pont
ACAriana Centa
Ariana Centa
MBMarcos Otávio Bueno
Marcos Otávio Bueno
Ricardo CerviniRicardo Cervini
Ricardo Cervini
CLClaudriana Locatelli
Claudriana Locatelli
The glyphosate herbicide is a pesticide widely used in the world and can contaminate soil, air, and water. The objective of this work was to evaluate the toxicity of a glyphosate‐based herbicide (GBH) in zebrafish (Danio rerio). Fish were exposed to different concentrations of GBH (0, 50, 250, and 500 µg/L) for 96 hours. Brain, liver, and blood were collected for biochemical and genotoxicity analyses, and behavioral tests were performed. The results showed that there was a reduction in the activity of the antioxidant enzymes of catalase (CAT) and glutathione‐S‐transferase (GST) in the liver at all concentrations and at the highest concentration in the brain. There was also a reduction in lipid peroxidation in the liver at all concentrations of glyphosate. There was an increase in micronuclei in the blood at the 500 µg/L concentration. However, the count of nuclear abnormalities showed no differences from the control. Interleukin‐1beta (IL‐1β) generation was inhibited at all concentrations in the liver and at the highest concentration in the brain. No significant differences were found in the behavioral test compared to the control. The results showed that acute exposure to GBH promoted an inflammatory event, which reduced the efficiency of antioxidants, thus producing a disturbance in tissues, mainly in the liver, causing immunosuppression and generating genotoxicity.